A Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia.

Trial Profile

A Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Burosumab (Primary)
  • Indications Osteomalacia; Rickets
  • Focus Adverse reactions
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 16 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 17 Aug 2015 Status changed from recruiting to active, no longer recruiting, as reported by Clinicaltrials.gov.
    • 15 Sep 2014 Results were presented at the Endocrine Society and The International Congress of Endocrinology in June 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top